![]() |
|
|
Vol. 60, Issue 4, 640-645, October 2001
Unité Propre de Recherche 415-Centre National de la Recherche Scientifique, Institut Cochin de Génétique Moléculaire, Paris, France.
| |
Abstract |
|---|
|
|
|---|
We have developed a procedure based on bioluminescence resonance energy transfer (BRET) to monitor the activation state of the insulin receptor in vitro. Human insulin receptor cDNA was fused to either Renilla luciferase (Rluc) or enhanced yellow fluorescent protein (EYFP) coding sequences. Fusion insulin receptors were partially purified by wheat-germ lectin chromatography from human embryonic kidney 293 cells cotransfected with these constructs. The conformational change induced by insulin on its receptor could be detected as an energy transfer (BRET signal) between Rluc and EYFP. BRET signal parallels insulin-induced autophosphorylation of the fusion receptor. Dose-dependent effects of insulin, insulin-like growth factor 1, and epidermal growth factor on BRET signal are in agreement with known pharmacological properties of these ligands. Moreover, antibodies that activate or inhibit the autophosphorylation of the receptor have similar effects on BRET signal. This method allows for rapid analysis of the effects of agonists on insulin receptor activity and could therefore be used in a high-throughput screening test for discovery of molecules with insulin-like properties.
| |
Introduction |
|---|
|
|
|---|
Insulin
exerts its biological effects through a plasma membrane receptor that
possesses a tyrosine kinase activity. Binding of insulin to its
receptor induces autophosphorylation of the receptor on tyrosine
residues and thereby stimulates its tyrosine kinase activity toward
intracellular substrates (such as IRS1 and Shc) that play crucial roles
in the transmission of the signal (White, 1997
; Virkamaki et al.,
1999
). Alterations in tyrosine phosphorylation of the insulin receptor
have been described in insulin resistance states such as diabetes and
obesity (Combettes-Souverain and Issad, 1998
). The discovery of
pharmacological agents that specifically activate the tyrosine kinase
activity of the insulin receptor will be of great importance for the
treatment of insulin resistant patients.
Phosphorylation of tyrosines 1158, 1162, and 1163, located in the
kinase domain of the insulin receptor, are known to play a critical
role in the regulation of the kinase activity of the receptor (Ellis et
al., 1986
; White et al., 1988
). The determination of the crystal
structure of the tyrosine kinase domain of the human insulin receptor
has provided a better understanding of the molecular mechanism involved
in the stimulation of the kinase activity of the receptor. In the
unphosphorylated state, the Tyr-1162 is located in the active site of
the enzyme and plays an autoinhibitory role by competing with the
binding of protein substrates (Hubbard et al., 1994
). This tyrosine
remains in the unphosphorylated form in the basal state, because other
residues in the activation loop also impair ATP binding. The
crystallization of the tris-phosphorylated form of the kinase domain
has shown that autophosphorylation of these three tyrosines results in
a dramatic change in the conformation of the activation loop (Hubbard,
1997
). This conformation change permits unrestricted access to the
binding sites for ATP and protein substrates. It has been postulated
that conformational changes induced by ligand binding move the kinase
domain of the two
-subunits of the receptor nearer to each other,
thereby allowing trans-phosphorylation of tyrosine 1162 and
adjacent tyrosines in the activation loop.
A procedure that allows monitoring of the conformational changes that
result in the activation of the kinase of the receptor would be a
valuable tool for the discovery of molecules with insulin-mimetic properties. Bioluminescence Resonance Energy Transfer (BRET) has been
described recently as a methodology that allows the study of
protein-protein interactions (Xu et al., 1999
; Angers et al., 2000
).
BRET is a naturally occurring phenomenon resulting from the transfer of
energy between luminescent donor and fluorescent acceptor proteins. The
strict dependence of the phenomenon on the molecular proximity between
energy donors and acceptors makes it a system of choice to study
changes in the interaction between two proteins. To study the
interaction between two partners, one of the partners is fused to
Renilla luciferase (Rluc), whereas the other is fused to a
yellow fluorescent protein (EYFP). The luciferase is excited by a
substrate (coelenterazine). If the two partners are less than 100 Å apart, an energy transfer occurs between the luciferase and the
fluorescent protein, and a signal emitted by the fluorescent protein
can be detected. In this article, we demonstrate that this method can
be used to monitor in vitro the activation state of the insulin receptor.
| |
Materials and Methods |
|---|
|
|
|---|
Expression Vectors.
The cDNA coding for the entire insulin
receptor sequence (Ebina et al., 1985
), with its stop codon replaced by
a NheI restriction site, was subcloned in frame with either
Renilla luciferase (Promega, Madison, WI) or the yellow
variant of GFP (EYFP; CLONTECH, Palo Alto, CA) in pcDNA3 expression
vector (Invitrogen, Groningen, The Netherlands). The presence of
restriction sites necessary to form the chimera introduced linkers of
six amino acids (ALALAT) between the insulin receptor and the
Renilla luciferase protein sequences, and eight amino acids
(ALALPVAT) between the insulin receptor and the EYFP protein sequences.
Moreover, a linker originating from EYFP plasmid, located in the 3'-end
of the IR-EYFP construct, added a short peptidic sequence
(GLRSRAQASNSAVDGTAGPIL) located at the C terminal end of IR-EYFP fusion protein.
Cell Culture, Transfection, and Partial Purification of Insulin
Receptor Fusion Proteins.
HEK 293 cells maintained in Dulbecco's
modified Eagle's medium supplemented with 4.5 g/l glucose and 10%
fetal bovine serum (Invitrogen, Cergy Pontoise, France) were
seeded at a density of 1.2 × 106 cells per
100-mm dish. Transient transfection was performed 1 day later using
FuGene 6 (Roche Diagnostics, Basel, Switzerland) with either 0.3 µg
of IR-Rluc cDNA and 0.3 µg of empty vector or with 0.3 µg of
IR-Rluc and 0.3 µg of IR-EYFP cDNAs per 100 mm dish. BRET
measurements on intact cells were performed essentially as described
previously (Angers et al., 2000
). Briefly, 2 days after transfection,
HEK-293 cells were detached with Trypsin-EDTA (Invitrogen) and
resuspended in phosphate-buffered saline. Approximately 60,000 cells
per well were distributed in a 96-well microplate. Cells were incubated
for 2 to 10 min in absence or presence of 100 nM insulin.
Coelenterazine was added at a final concentration of 5 µM, and
light-emission acquisition was started immediately as described below.
In some experiments, BRET measurements were performed using adherent
cells. Cells were transfected exactly as described above, but 1 day
after transfection, cells were transferred into 96-well microplates
(white culturPlate-96; Packard, Meriden, CT) at a density of 30,000 cells per well. BRET measurements were directly performed in these
microplates on the following day exactly as described above.
80°C for subsequent use. Protein
concentration in the partially purified fusion receptor preparation was
measured using a Bradford assay.
BRET Assay on Partially Purified Fusion Receptors.
In vitro
measurement of BRET signal was performed using 4.5 µl of wheat-germ
lectin (WGL) eluate (approximately 2 µg of proteins) preincubated in
96-well microplates for 45 min at 20°C in a total volume of 60 µl
containing 30 mM MOPS, 1 mM
Na3VO4, and different concentrations of ligands. Coelenterazine (7 µl; final concentration, 2.6 µM; Molecular Probes, Inc., Eugene, OR) was added to the
preparation and light emission acquisition at 485 nm (filter window, 20 nm) and 530 nm (filter window, 25 nm) was started immediately using the
Fusion microplate analyser (Packard). The BRET ratio has been defined
previously (Angers et al., 2000
) as: [(emission at 530 nm)
(emission at 485 nm) × Cf] / (emission at 485 nm), where Cf
corresponds to (emission at 530 nm) / (emission at 485 nm) for the Rluc
fusion protein expressed alone in the same experimental conditions
(i.e., in our study, IR-Rluc transfected alone in HEK-293 cells). For
the sake of readability, results were expressed in milliBRET units
(mBU); 1 mBU corresponds to the BRET ratio multiplied by 1000.
Autophosphorylation of Partially Purified Fusion Insulin
Receptors.
Partially purified fusion insulin receptors (4.5 µl)
were preincubated for 45 min at 20°C in a total volume of 60 µl
containing 30 mM MOPS, 12 mM MgCl2, 2 mM
MnCl2, 1 mM
Na3VO4, and different concentrations of ligands. Autophosphorylation reaction was initiated by adding 5 µl of ATP (final concentration, 100 µM) for 2 min and
stopped by addition of SDS-polyacrylamide gel electrophoresis sample
buffer (Tavaré and Denton, 1988
). Autophosphorylation of the
fusion receptors was assessed by immunoblotting (Issad et al., 1995
)
using 4G10 antiphosphotyrosine antibody (UBI, Lake Placid, NY).
Autophosphorylation of Fusion Insulin Receptors in Intact
Cells.
Forty-eight hours after transfection, HEK-293 cells were
incubated for 5 min in the absence or presence of insulin and extracted as described previously (Tavaré et al., 1988
). Soluble extracts were incubated for 2 h at 4°C with 50 µl of WGL-Sepharose and partially purified proteins were subjected to Western blotting (Issad
et al., 1995
) using enhanced chemiluminescence (Amersham Pharmacia
Biotech, Saclay, France).
| |
Results and Discussion |
|---|
|
|
|---|
Expression of Insulin Receptor Fused to Rluc and EYFP in HEK-293
Cells.
The conformational change induced by insulin on its
receptor is believed to bring the two
-subunits nearer to each
other, thus allowing trans-phosphorylation of one subunit by
the other subunit. To detect this conformational change using the BRET
method, the coding sequence of the insulin receptor was fused to either Rluc or EYFP (Fig. 1A). Fluorescent
microscopy shows that HEK-293 cells transfected with the cDNA coding
for IR-EYFP alone or both IR-Rluc and IR-EYFP expressed the fluorescent
fusion protein at the plasma membrane (Fig. 1B).
|
-subunit fused
to Rluc or EYFP. These results indicate that these fusion insulin
receptor proteins are correctly expressed at the plasma membrane and
have conserved insulin-induced autophosphorylation activity.
Insulin Stimulates Bioluminescence Resonance Energy Transfer
between
-IR-Rluc and
-IR-EYFP in Vitro.
BRET measurements
performed on intact HEK-293 cells cotransfected with IR-Rluc and
IR-EYFP showed that insulin has only a modest effect on BRET signal
(Fig. 2A). Similar results were obtained when BRET signal was directly measured on adherent HEK-293 cells (results not shown). Moreover, these results were not cell-type specific, because equivalent results where obtained when BRET measurements were performed using Chinese hamster ovary (CHOK1) or
monkey kidney (COS1) cells. Finally, varying the ratio of transfected IR-Rluc cDNA to IR-EYFP cDNA (from 0.1 to 10) did not improve insulin
effect on BRET signal (results not shown).
|

Rluc]2, [
EYFP]2, and hybrid molecules
[
Rluc]-[
EYFP]. Therefore, a BRET signal can
theoretically result from either an intramolecular energy transfer
within the same [
Rluc]-[
EYFP] molecule or from an
intermolecular energy transfer between two fusion-receptor molecules
(for instance between an [
Rluc]2 molecule
and an [
EYFP]2 molecule). Increasing the
amount of WGL-eluate in the reaction mixture from 2 µl to 10 µl
(i.e., increasing the concentration of partially purified proteins in
the assay from 15 ng/µl to 75 ng/µl) did not affect BRET signal
(Fig. 2B). This indicates that BRET signal measured on partially
purified fusion receptors is independent of protein concentration and
reflects an intramolecular energy transfer between
-RLuc and
-EYFP within the same ([
Rluc]-[
EYFP]) molecule.
Moreover, no BRET signal could be detected when WGL-eluates from cells
transfected with IR-Rluc alone were mixed with WGL-eluates from cells
transfected with IR-EYFP alone (results not shown). This indicates that
no energy transfer occurs between [
Rluc]2 and [
EYFP]2 and further supports the
notion that the observed energy transfer is an intramolecular process
that reflects a conformational change within a
[
Rluc]-[
EYFP] fusion receptor.
Fig. 3A shows that insulin stimulates in
vitro the autophosphorylation of the partially purified fusion
receptors. The effect of insulin on the autophosphorylation (Fig. 3B)
is on the same order of magnitude (2.5- to 3-fold) as the effect of
insulin on BRET signal (Fig. 3C). This result indicates that the BRET
signal can be considered a representative measurement of the activation state of the insulin receptor. The in vitro effect of insulin on BRET
signal (Figs. 2 and 3C) was observed in the absence of ATP in the
incubation medium. This indicates that this signal reflects the
conformational change induced by insulin before any phosphorylation
event. No further increase in BRET signal was observed upon addition of
ATP (Fig. 3C). As discussed previously, partially purified receptor
preparations are likely to contain [
Rluc]2,
[
EYFP]2, and hybrid
[
Rluc]-[
EYFP] molecules. We observed that
[
Rluc]2 and
[
EYFP]2 fusion receptors are capable of
autophosphorylation, both in intact cells (Fig. 1C) and in vitro
(results not shown). However, there is no direct evidence that hybrid
receptors are capable of autophosphorylation. Therefore, we cannot
exclude the possibility that the fraction of receptors that is
responsible for insulin-induced BRET signal ([
Rluc]-[
EYFP] hybrid receptors) do not undergo
autophosphorylation. If this is the case, autophosphorylation-induced
conformational change will remain undetectable. On the other hand, it
is also possible that although hybrid receptors do undergo
autophosphorylation, the resulting conformational change in the kinase
domain (Hubbard, 1997
|
Dose-Dependent Effect of Insulin, IGF1, and EGF on BRET
Signal.
The effect of increasing concentrations of insulin on BRET
signal is shown on Fig. 4A. Maximal
insulin effects were obtained around 15 nM. The half-maximal effect of
insulin (EC50) was observed at 5 nM insulin. IGF1
also dose-dependently stimulated BRET signal, with an
EC50 value of about 200 nM. EGF had no effect on
BRET signal. These results are in agreement with known pharmacological properties of these ligands toward the insulin receptor.
Autophosphorylation of the fusion receptor in response to these ligands
follows similar dose-dependent patterns, indicating that BRET signal
indeed reflects the activation state of the insulin receptor (Fig. 4B).
|
Effect of Anti-Insulin Receptor Antibodies on BRET Signal.
83-14 is a monoclonal antibody directed against the
-subunit of the
insulin receptor (Soos et al., 1986
), which has insulin-like activity
on human adipocyte metabolism (Taylor et al., 1987
) and on insulin
receptor autophosphorylation (O'Brien et al., 1987
). Interestingly,
this antibody also fully activated insulin receptors from an
insulin-resistant patient that could not be activated by insulin
because of a mutation that impairs insulin binding (Krook et al.,
1996
). We observed that 83-14 strongly stimulates BRET signal (Fig.
5A). Previous work has shown that,
unexpectedly, maximal effect of insulin on autophosphorylation can be
further increased by 83-14 antibody, leading to supramaximal activation of the autophosphorylation of the insulin receptor when both ligands are present together. Similarly, combined incubation of the fusion receptor with both insulin and 83-14 also results in a BRET signal that
is higher than the maximal effect obtained with insulin alone. The
effect of 83-14 antibody on BRET signal is likely to correspond to an
intramolecular conformational change. Indeed, this effect was not
affected by increasing the amount of partially purified proteins in the
assay (results not shown). Moreover, no BRET signal could be induced by
83-14 antibody when WGL-eluates from cells transfected with IR-Rluc
alone were mixed with WGL-eluates from cells transfected with IR-EYFP
alone.
|
| |
Conclusion |
|---|
|
|
|---|
We have developed an assay, based on bioluminescence resonance
energy transfer, that monitors conformational changes within the
insulin receptor. The BRET signal detected in this assay closely reflects the activation state of the receptor. Thus, our procedure allows for very rapid determination of the activation state of the
insulin receptor and can be easily used in a high-throughput screening
test for the search of novel molecules with insulin-like activities.
Indeed, partially purified fusion insulin receptors can be prepared on
a large scale by WGL-chromatography and stored at
80°C for
subsequent use. This preparation can be distributed in an automated way
in 96-well microplates and the effect of molecules on insulin receptor
activity can be measured within a few minutes using the BRET method. We
thus believe that this assay will be a valuable tool for the search of
molecules with therapeutic properties.
| |
Acknowledgments |
|---|
We are very grateful to Dr. Ralf Jockers for valuable help and discussions on BRET. We also thank Stefano Marullo and Michel Bouvier for useful discussions and Pierre-Olivier Couraud for encouragement during the course of this study. We thank Kenneth Siddle and Jeremy Tavaré for providing us with anti-insulin receptor antibodies 83-14 and AK766. We also thank Marc Stanislawski for providing us with anti-mouse IgG peroxidase-coupled antibody used in immuno-blotting experiments.
| |
Footnotes |
|---|
Received May 7, 2001; Accepted June 15, 2001
This work was supported the Center National de la Recherche Scientifique, the Association pour la Recherche sur le Cancer, the Ligue contre le Cancer, and by a Roche-Pharma-Association de Langue Française d'Etude du Diabète et des Maladies Métaboliques) research grant.
Dr. Tarik Issad, UPR415-CNRS, Institut Cochin de Génétique Moléculaire, 22 rue Méchain, 75014 Paris, France. E-mail: issad{at}cochin.inserm.fr
| |
Abbreviations |
|---|
BRET, bioluminescence resonance energy transfer; EYFP, enhanced yellow fluorescent protein; Rluc, Renilla luciferase; HEK, human embryonic kidney; MOPS, 4-morpholinepropanesulfonic acid; WGL, wheat-germ lectin; mBU, milliBRET unit; IR, insulin receptor; IGF, insulin-like growth factor; EGF, epidermal growth factor.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. Blanquart, C. Gonzalez-Yanes, and T. Issad Monitoring the Activation State of Insulin/Insulin-Like Growth Factor-1 Hybrid Receptors Using Bioluminescence Resonance Energy Transfer Mol. Pharmacol., November 1, 2006; 70(5): 1802 - 1811. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. U. Gehret, A. Bajaj, F. Naider, and M. E. Dumont Oligomerization of the Yeast {alpha}-Factor Receptor: IMPLICATIONS FOR DOMINANT NEGATIVE EFFECTS OF MUTANT RECEPTORS J. Biol. Chem., July 28, 2006; 281(30): 20698 - 20714. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Blanquart, N. Boute, D. Lacasa, and T. Issad Monitoring the Activation State of the Insulin-Like Growth Factor-1 Receptor and Its Interaction with Protein Tyrosine Phosphatase 1B Using Bioluminescence Resonance Energy Transfer Mol. Pharmacol., September 1, 2005; 68(3): 885 - 894. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cluet, C. Bertsch, C. Beyer, L. Gloeckler, M. Erhardt, J.-P. Gut, J.-L. Galzi, and A.-M. Aubertin Detection of Human Immunodeficiency Virus Type 1 Nef and CD4 Physical Interaction in Living Human Cells by Using Bioluminescence Resonance Energy Transfer J. Virol., July 1, 2005; 79(13): 8629 - 8636. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lacasa, N. Boute, and T. Issad Interaction of the Insulin Receptor with the Receptor-Like Protein Tyrosine Phosphatases PTP{alpha} and PTP{epsilon} in Living Cells Mol. Pharmacol., April 1, 2005; 67(4): 1206 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ayoub, A. Levoye, P. Delagrange, and R. Jockers Preferential Formation of MT1/MT2 Melatonin Receptor Heterodimers with Distinct Ligand Interaction Properties Compared with MT2 Homodimers Mol. Pharmacol., August 1, 2004; 66(2): 312 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vrecl, R. Jorgensen, A. Pogacnik, and A. Heding Development of a BRET2 Screening Assay Using {beta}-Arrestin 2 Mutants J Biomol Screen, June 1, 2004; 9(4): 322 - 333. [Abstract] [PDF] |
||||
![]() |
M. M. Berglund, D. A. Schober, M. A. Esterman, and D. R. Gehlert Neuropeptide Y Y4 Receptor Homodimers Dissociate upon Agonist Stimulation J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1120 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Couturier and R. Jockers Activation of the Leptin Receptor by a Ligand-induced Conformational Change of Constitutive Receptor Dimers J. Biol. Chem., July 11, 2003; 278(29): 26604 - 26611. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Berglund, D. A. Schober, M. A. Statnick, P. H. McDonald, and D. R. Gehlert The Use of Bioluminescence Resonance Energy Transfer 2 to Study Neuropeptide Y Receptor Agonist-Induced {beta}-Arrestin 2 Interaction J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 147 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ayoub, C. Couturier, E. Lucas-Meunier, S. Angers, P. Fossier, M. Bouvier, and R. Jockers Monitoring of Ligand-independent Dimerization and Ligand-induced Conformational Changes of Melatonin Receptors in Living Cells by Bioluminescence Resonance Energy Transfer J. Biol. Chem., June 7, 2002; 277(24): 21522 - 21528. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||